Xvivo Perfusion AB
STO:XVIVO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
256.5
539
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Xvivo Perfusion AB
Cash Taxes Paid
Xvivo Perfusion AB
Cash Taxes Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cash Taxes Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Xvivo Perfusion AB
STO:XVIVO
|
Cash Taxes Paid
kr11.1m
|
CAGR 3-Years
127%
|
CAGR 5-Years
38%
|
CAGR 10-Years
11%
|
||
O
|
OssDsign AB
STO:OSSD
|
Cash Taxes Paid
kr677k
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
D
|
Doxa AB
STO:DOXA
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bactiguard Holding AB
STO:BACTI B
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
V
|
Vimian Group AB
STO:VIMIAN
|
Cash Taxes Paid
€11.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Cash Taxes Paid
kr17.1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Xvivo Perfusion AB
Glance View
Xvivo Perfusion AB is a medical technology company. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 92 full-time employees. The company went IPO on 2012-10-08. The firm operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The firm markets its products in Europe, Asia, Middle East, and North & South America.
See Also
What is Xvivo Perfusion AB's Cash Taxes Paid?
Cash Taxes Paid
11.1m
SEK
Based on the financial report for Sep 30, 2024, Xvivo Perfusion AB's Cash Taxes Paid amounts to 11.1m SEK.
What is Xvivo Perfusion AB's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 10Y
11%
Over the last year, the Cash Taxes Paid growth was 608%. The average annual Cash Taxes Paid growth rates for Xvivo Perfusion AB have been 127% over the past three years , 38% over the past five years , and 11% over the past ten years .